These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35596946)

  • 1. Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model.
    Paranthaman K; Subbarao S; Andrews N; Kirsebom F; Gower C; Lopez-Bernal J; Ramsay M; Copas A
    Age Ageing; 2022 May; 51(5):. PubMed ID: 35596946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort.
    Goldin S; Adler L; Azuri J; Mendel L; Haviv S; Maimon N
    Gerontology; 2022; 68(12):1350-1357. PubMed ID: 35134810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
    Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
    JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
    Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
    Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study.
    Stirrup O; Shrotri M; Adams NL; Krutikov M; Azmi B; Monakhov I; Tut G; Moss P; Hayward A; Copas A; Shallcross L
    Age Ageing; 2023 Aug; 52(8):. PubMed ID: 37595069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities.
    Muhsen K; Maimon N; Mizrahi AY; Boltyansky B; Bodenheimer O; Diamant ZH; Gaon L; Cohen D; Dagan R
    JAMA Intern Med; 2022 Aug; 182(8):859-867. PubMed ID: 35737368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
    Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study.
    Grewal R; Kitchen SA; Nguyen L; Buchan SA; Wilson SE; Costa AP; Kwong JC
    BMJ; 2022 Jul; 378():e071502. PubMed ID: 35793826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Dose Coronavirus 2019 Vaccination Coverage among the Residents of Long-Term Care Facilities in France.
    Belmin J; Lutzler P; Hidoux P; Drunat O; Lafuente-Lafuente C;
    Gerontology; 2022; 68(5):546-550. PubMed ID: 34380133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
    Trigueros M; Pradenas E; Palacín D; Muñoz-López F; Ávila-Nieto C; Trinité B; Bonet-Simó JM; Isnard M; Moreno N; Marfil S; Rovirosa C; Puig T; Grau E; Chamorro A; Martinez A; Toledo R; Font M; Ara J; Carrillo J; Mateu L; Blanco J; Clotet B; Prat N; Massanella M;
    Age Ageing; 2022 May; 51(5):. PubMed ID: 35595256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales.
    Kerr S; Bedston S; Bradley DT; Joy M; Lowthian E; Mulholland RM; Akbari A; Hobbs FDR; Katikireddi SV; de Lusignan S; Rudan I; Torabi F; Tsang RSM; Lyons RA; Robertson C; Sheikh A
    Int J Epidemiol; 2023 Feb; 52(1):22-31. PubMed ID: 36272418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI).
    Stirrup O; Shrotri M; Adams NL; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
    Open Forum Infect Dis; 2023 Jan; 10(1):ofac694. PubMed ID: 36713473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study.
    Suah JL; Husin M; Tok PSK; Tng BH; Thevananthan T; Low EV; Appannan MR; Muhamad Zin F; Mohd Zin S; Yahaya H; Peariasamy KM; Sivasampu S
    Int J Infect Dis; 2022 Jun; 119():69-76. PubMed ID: 35331933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.